ArticleGastro hep advances2026
Development and External Validation of an Algorithm for Identifying HDV RNA-Positive Patients.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Accurate detection and treatment of hepatitis D virus (HDV)-infected patients can reduce disease-related morbidity and mortality. This study developed and validated real-world evidence-based algorithms to detect ribonucleic acid (RNA)-positive HDV patients from administrative claims data. Methods: This retrospective observational study identified hepatitis B virus and HDV patients from laboratory testing data linked to administrative claims (HealthVerity; 2015-2022), with external validation performed using electronic health records (TriNetX; 2005-2023). Both diagnosis-based and machine learning algorithms were evaluated. Performance metrics included area under the receiver-operating characteristic curve (AUROC), area under the precision-recall curve, sensitivity, specificity, positive predictive value, and accuracy. Internal validation results showed that diagnosis code-based algorithms identified HDV RNA-positivity with ≥88% accuracy. Results: The best-performing algorithm-based approach in terms of optimism-adjusted AUROC was a random forest model with the following covariates: age, gender, hepatitis complications, HDV, and hepatitis B virus diagnosis, inpatient/outpatient diagnosis, hepatitis medication, and physician specialty (AUROC 97%). Decision curve analysis showed that the random forest algorithm with covariates excluding physician specialty, both inpatient/outpatient diagnosis, and physician specialty performed best. External validation indicated the random forest algorithm using equivalent covariates but without physician specialty had the best performance (positive predictive value 34%; accuracy 92%). Conclusion: Algorithms based on HDV diagnosis were more effective for identifying HDV RNA-positive patients than algorithms using HDV-based variables from claims data. Further research into improving such algorithms is needed. Although fair discrimination may occur without claims data, key metrics were not able to replace traditional testing methods. The proposed models could help identify high-risk patients where certain strategies could be prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.